Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Operating Expenses (2016 - 2026)

Perspective Therapeutics' Operating Expenses history spans 17 years, with the latest figure at $28.4 million for Q1 2026.

  • On a quarterly basis, Operating Expenses rose 27.88% to $28.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $120.6 million, a 19.22% increase, with the full-year FY2025 number at $114.4 million, up 23.94% from a year prior.
  • Operating Expenses hit $28.4 million in Q1 2026 for Perspective Therapeutics, down from $39.9 million in the prior quarter.
  • Over the last five years, Operating Expenses for CATX hit a ceiling of $45.2 million in Q4 2024 and a floor of $2.8 million in Q1 2022.
  • Historically, Operating Expenses has averaged $17.3 million across 5 years, with a median of $13.3 million in 2024.
  • Biggest five-year swings in Operating Expenses: soared 276.41% in 2024 and later dropped 11.82% in 2025.
  • Tracing CATX's Operating Expenses over 5 years: stood at $5.6 million in 2022, then soared by 113.72% to $12.0 million in 2023, then soared by 276.41% to $45.2 million in 2024, then dropped by 11.82% to $39.9 million in 2025, then dropped by 28.89% to $28.4 million in 2026.
  • Business Quant data shows Operating Expenses for CATX at $28.4 million in Q1 2026, $39.9 million in Q4 2025, and $28.1 million in Q3 2025.